Severe Acute Respiratory Syndrome–associated Coronavirus in Lung Tissue by Mazzulli, Tony et al.
Efforts to contain severe acute respiratory syndrome
(SARS) have been limited by the lack of a standardized,
sensitive, and specific test for SARS-associated coron-
avirus (CoV). We used a standardized reverse transcrip-
tion-polymerase chain reaction assay to detect SARS-CoV
in lung samples obtained from well-characterized patients
who died of SARS and from those who died of other rea-
sons. SARS-CoV was detected in all 22 postmortem lung
tissues (to 109 viral copies/g) from 11 patients with proba-
ble SARS but was not detected in any of the 23 lung con-
trol samples (sample analysis was blinded). The sensitivity
and specificity (95% confidence interval) were 100%
(84.6% to 100%) and 100% (85.1% to 100%), respectively.
Viral loads were significantly associated with a shorter
course of illness but not with the use of ribavirin or steroids.
CoV was consistently identified in the lungs of all patients
who died of SARS but not in control patients, supporting a
primary role for CoV in deaths.
F
rom its origins in November 2002 in Guangdong
Province, China, severe acute respiratory syndrome
(SARS) has become an emerging infectious disease that
has spread to areas throughout the world, including Hong
Kong, Vietnam, Singapore, Taiwan, and Canada (1).
Although controversy remains over the etiology of SARS,
the World Health Organization has declared a newly
described virus known as the SARS-associated coron-
avirus (SARS-CoV) as the cause (2). This announcement
has led to a rapid proliferation of different in-house labo-
ratory tests aimed at detecting either SARS-CoV–specific
antibodies or SARS-CoV nucleic acid in clinical speci-
mens. The Centers for Disease Control and Prevention def-
inition for a confirmed case of SARS includes the results
of these laboratory tests (3). However, because different
assays are being used, comparing results from different
centers has been difficult. In addition, the inability of these
nonstandardized tests to detect SARS-CoV in all cases has
led to speculation that other agents may be associated with
SARS. Some researchers have suggested that illnesses that
progress to respiratory failure and death may not be caused
by uncontrolled viral replication but rather are the result of
an immunopathologic process (4). In a recent report of six
fatal cases of SARS, SARS-CoV was detected by reverse
transcriptase-polymerase chain reaction (RT-PCR) in post-
mortem lung tissue in only four patients (5).
The purpose of this study was to use a standardized,
commercially available, RT-PCR assay to test for the pres-
ence of SARS-CoV RNA. Lung tissue obtained at autopsy
from well-characterized patients with SARS who died dur-
ing the outbreak in Canada were compared to lung samples
obtained at autopsy from patients without SARS who died
during the outbreak and lung samples from patients who
died before the outbreak.
Methods
Patients
All patients who met the current World Health
Organization case definition of probable SARS and who
underwent a postmortem examination in Canada during
the March–April 2003 outbreak were included in this
study. Clinical details were extracted retrospectively from
hospital records. Clinical descriptions of some of these
cases have been published separately (6,7). As of May 14,
2003, a total of 24 patients died of SARS in Canada; all
died in Toronto. Of the 24 patients, autopsies were per-
formed on 11 patients. Results of ante- and postmortem
examination for routine bacterial and viral respiratory
pathogens from these 11 patients, as described elsewhere,
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A total of 22 discrete postmortem lung samples collect-
ed from these 11 patients were included in this analysis. An
additional 13 postmortem lung samples from 7 patients
who died during the SARS outbreak but whose deaths were
attributed to other causes were also included. The attributed
cause of death in these patients was as follows: a 46-year-
old woman died of invasive group A streptococcal infec-
tion; a 93-year-old man died of congestive heart failure; a
37-year-old man died of sudden death cardiovascular dis-
ease; a 74-year-old man died of amiodarone pulmonary
toxicity; a 78-year-old woman died of dementia and aspira-
tion pneumonia; a 47-year-old woman died of diabetes and
congestive heart failure; and an 81-year-old man died of
bladder cancer and aspiration pneumonia. In addition, 10
lung samples collected in 1998 from 10 patients (4 women
and 6 men; age range 54–75 years) with lung cancer were
also included as negative controls. All samples collected at
the time of autopsy were snap frozen in a mixture of
absolute ethanol and dry ice and subsequently stored at
–70°C until tested. The samples were coded and then
processed, subjected to RT-PCR analysis, and interpreted
before the identity of the samples was divulged. This study
was approved by theresearch ethics boards at Mount Sinai
Hospital and the University Health Network.
RT-PCR
Lung tissue samples were thawed and immediately
homogenized in lysis buffer (QIAGEN, Mississauga,
Canada) with disposable tissue grinders (Kendall
Precision, Mansfield, MA). The homogenate was passed
through QIAshredder columns (QIAGEN) before RNA
isolation by using the RNeasy Mini Kit (QIAGEN). The
sample was eluted in 30 µL of RNAse free water. The RT-
PCR was carried out by using the RealArt HPA-
Coronavirus LightCycler RT Reagents Assay (Artus
GmbH, Hamburg, Germany) with a LightCycler real-time
platform (Roche Diagnostics, Laval, Canada). The HPA-
Coronavirus Master Mix contains reagents and enzymes
for the specific amplification of an 80-bp region of the
SARS-CoV polymerase gene from 5 µL of RNA with the
primer pairs published by the Bernhard-Nocht Institute
(Hamburg, Germany) as posted on the World Health
Organization Web site (available from: URL:
http://www.who.int/csr/sars/primers/en/).
Viral load was calculated from a standard curve based
on four external positive controls (quantification stan-
dards) included in the RealArt HPA-Coronavirus
LightCycler RT Reagents Assay kit (Figure A and B). The
standards were treated as previously purified samples, and
the same 5-mLvolume was added per capillary. Astandard
preparation of SARS-CoV isolated from cell culture super-
natants of VeroE6 cells was used as a calibrator in each
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Figure. RealArt HPA-Coronavirus LightCycler reverse transcrip-
tion-polymerase chain reaction (RT-PCR) assay results. PCR
results from 5 µL RNA are displayed in channel F1/F2 of the
LightCycler instrument (A). Four quantification standards are
included in the assay to generate a standard curve (B). An inter-
nal control, added at the RNA isolation stage, is used to monitor
both the quality of the RNA isolation as well as possible PCR inhi-
bition (C).run. In addition, the kit contains a second heterologous
amplification system (i.e., an internal control) to identify
either PCR inhibition exclusively, if added to the extracted
RNA, or RNA isolation quality as well as PCR inhibition,
if added during the RNA isolation procedure (Figure C).
Although the assay insert states that the primers and probes
used in the assay were checked for possible similarity to
other pathogens by means of sequence comparison, 25 ran-
domly chosen amplicons from our sample pool were inde-
pendently sequenced to confirm SARS-CoV–specific
amplification and detection. Univariate analysis compar-
ing potential predictors of viral load (e.g., duration of ill-
ness, the use of ribavirin, the use of steroids) was complet-
ed by using Fisher exact test. Two-sided p values <0.05
were considered significant.
Results
The clinical description and RT-PCR results for the 11
patients with probable SARS from whom postmortem lung
tissue samples were examined are summarized in Table 1.
The mean age of the 11 patients was 70 years (range
43–99). Six of the 11 patients were men. All but 1 of the 11
patients had underlying coexisting conditions, the most
common of which was diabetes mellitus in 6 patients. The
mean duration of illness was 20 days (range 8–32). Seven
patients had been intubated and mechanically ventilated
before death. Three patients had requested not to be intu-
bated (information on ventilation was not available for one
patient). Ten of the 11 patients were treated with ribavirin;
6 of the 11 patients were treated with steroids.
SARS-CoV was detected in all 22 postmortem lung tis-
sue samples collected from all 11 patients who died with a
diagnosis of probable SARS. All 13 postmortem lung sam-
ples from the seven non-SARS fatalities that occurred dur-
ing the SARS outbreak were negative for SARS-CoV, as
were all 10 lung-tissue samples collected from patients
with lung cancer 5 years before the outbreak (Table 2). The
corresponding sensitivity and specificity of the RealArt
HPA-Coronavirus LightCycler RT Reagent assay are both
100% (95% confidence interval [CI] for sensitivity 84.6%
to 100%; 95% CI for specificity 85.1% to 100%) for the
detection of SARS-CoV.
The SARS-CoV viral load in postmortem lung tissue
ranged from 2.7 x 104 copies/g tissue to 3.8 x 109 copies/g
RESEARCH
22 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 1, January 2004
Table 1. Clinical description and SARS-CoV RT-PCR results for 11 patients who died with probable SARS
a 
Illness and treatment duration (days) 
RealArt HPA Coronavirus  
RT-PCR
b 
Sex/age  Coexisting conditions  Illness  Ventilation  Ribavirin  Steroids 
Postmortem lung 
tissue description  Results 
Copies of  
CoV/g tissue 
RUL  Positive
  1.5 x 10
8 
RML (#1)  Positive  5.4 x 10
7 
RML (#2)  Positive  2.8 x 10
7 
RML (#3)  Positive  7.4 x 10
6 
M/43  Type II DM, HTN  15  4  0  0 
RML (#4)  Positive  6.4 x 10
8 
M/76  Type II DM, CAD, 
HTN 
11  4  6 (started on day 
6 of illness) 
0  Lung  Positive
  3.8 x 10
9 
RT lung  Positive
  1.0 x 10




8  5  >5 (started on 
day 4 of illness) 
0 
LUL  Positive  9.4 x 10
7 
M/62  Rectal cancer, HTN, 
hypercholesterolemia 
8  N/A  >5 (started on 
day 4 of illness) 
0  LT lung  Positive
  5.3 x 10
7 
LT lung  Positive
  3.0 x 10
4  F/73  HTN, 
hypercholesterolemia 
28  DNI  14 (started on 
day 5 of illness) 
12 (stated on day 
14 of illness)  RT lung  Positive  3.6 x 10
5 
F/99  Osteoarthritis  26  DNI  13 (started on 
day 1 of illness) 
0  Lung  Positive  5.0 x 10
4 
RUL lung  Positive  3.2 x 10
6  M/63  Hypercholesterolemia, 
cerebral vascular disease 
20  12  16 (started on 
day 4 of illness) 
16 (started on 
day 6 of illness)  LLL  Positive  2.5 x 10
7 
LT lung  Positive
  4.1 x 10
5  F/78  Type II DM, HTN, 
hypercholesterolemia 
24  18  10 (started on 
day 3 of illness) 
18 (started on 
day 5 of illness)  RUL  Positive  4.9 x 10
5 
RT lung  Positive  7.6 x 10
4  M/44    29  18  18 (started on 
day 8 of illness) 
17 (started on 
day 12 of illness)  LT lung  Positive  4.1 x 10
4 
LLL  Positive  5.6 x 10
5  M/77  Type II DM, HTN, 
hypercholesterolemia 
>18  >1  >1 (started on 
day 10 of illness) 
>7 (started on 
day 10 of illness)  LUL  Positive  5.7 x 10
5 
LT lung  Positive  2.7 x 10
4  F/79  Type II DM, HTN, 
hypercholesterolemia 
32  DNI  11 (started on 
day 2 of illness) 
>4 (started on 
day 12 of illness)  Lung  Positive  2.1 x 10
5 
aSARS, severe acute respiratory syndrome; CoV, coronavirus; RT-PCR, reverse transcription polymerase chain reaction; F, female; M, male; DM, diabetes mellitus; 
HTN, hypertension; RUL, right upper lobe; RML, right middle lobe; CAD, coronary artery disease; RT, right; LT, left; LUL, left upper lobe; LLL, left lower lobe; N/A, 
not available; DNI, “Do not intubate” order written. 
bRealArt HPA Coronavirus RT-PCR
 (Artus GmbH, Hamburg, Germany). tissue. Higher viral loads (>106 copies/g tissue) were asso-
ciated with patients who had a shorter duration of illness
(<21 days) (p=0.002, Fisher exact test). The use of rib-
avirin or steroids was not significantly associated with
viral load levels (Table 2).
Twenty-five randomly selected amplicons from the
sample pool were sequenced to assess specificity and pos-
sible cross-reactivity to other pathogens. A BLAST (avail-
able from: URL: http://www.ncbi.nlm.nih.gov/BLAST/)
search performed against the SARS-CoV genomes in
GenBank, European Molecular Biology Laboratory, DNA
Data Bank of Japan, and Protein Data Bank on the
National Center for Biotechnology Information Web site
(available from: URL: http://www.ncbi.nlm.nih.gov/),
indicated that all amplicon samples contained SARS-CoV
polymerase gene sequence. 
Discussion
By using a standardized RT-PCR assay, SARS-CoV has
been unequivocally identified in the lung tissue of all
patients who died with probable SARS but not in any of
the controls. These observations support a primary role for
this virus in patients with SARS who have fatal outcomes
and provide additional, strong evidence to fulfill Koch’s
postulates regarding SARS-CoV as the cause of SARS (8).
SARS-CoV was found in different lung samples from the
same patient, suggesting that the virus is widely dissemi-
nated throughout the lung at the time of death. Previous
studies suggested that progression of disease to respiratory
failure may be primarily mediated by host immune
response rather than viral replication (4). Although viral
RNA in lung tissue does not necessarily indicate replicat-
ing virus, virus in multiple lung lobes, often in high copy
number, at the time of death suggests that SARS-CoV may
also be contributing to disease progression. The fact that
higher viral loads were significantly associated with
patients with a shorter duration from onset of illness to
death supports the role of viral replication as a contributor
to death. Ten of the 11 patients had received therapy with
ribavirin, and 6 patients were treated with steroids. The
failure to eradicate SARS-CoV despite ribavirin therapy
and the lack of association between the use of ribavirin and
SARS-CoV viral load are consistent with in vitro data
showing that ribavirin has no activity against this agent
(9). 
Global efforts to contain SARS have been severely
impeded by the lack of a standardized, sensitive, and spe-
cific diagnostic test for SARS-CoV. Different diagnostic
strategies, including culture, serologic assays, and molec-
ular detection methods, have been described, but each of
these tests has limitations. In-house RT-PCR assays have
been associated with sensitivities as low as 50% in patients
with SARS (10), which raises uncertainty about the role of
CoV versus co-pathogens in mediating severe or fatal
SARS. By contrast, the sensitivity and specificity of the
RealArt HPA-Coronavirus RT-PCR assay for detecting
CoV in lung tissue samples appear to be excellent. In addi-
tion, with the real-time LightCycler system, the assay gen-
erates quantitative results within 1 hour, which is much
shorter than traditional PCR reactions. 
The type of specimen tested, the timing of sample col-
lection, (i.e., acute versus convalescent phase) the method
of specimen collection, as well as the method of sample
preservation may have substantial impact on the results
obtained from a diagnostic test. The lower sensitivity of
SARS-CoV detection reported by Peiris et al. (10) may be
a consequence of these confounding factors. Our study
design of examining lung biopsies from clearly defined
patient populations overcame confounding issues, such as
sampling technique, nonspecific case definitions, and pos-
sible undocumented exposure to SARS. Given the pre-
dominance of respiratory symptoms in patients with
SARS, lung samples have perhaps the highest viral titers
of all specimen types; yet in nonfatal cases, obtaining rou-
tine lung biopsies is not practical. Other respiratory tract
specimens may be satisfactory substitutes for biopsies, but
further studies examining the prevalence of SARS-CoV in
these other specimen types and in a larger population are
needed. With the use of standardized commercially avail-
able assays, comparison of results from different centers
may be facilitated.
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Table 2. Univariate analysis of predictors of high viral loads in postmortem lung tissue 
Predictor  Viral load >10
6 copies/g lung tissue  Viral load <10
6 copies/g lung tissue  Fisher exact test 
Short duration of illness (<21 d)  5/5  0/6  p=0.002 
Use of ribavirin  4/5  6/6  p=0.45 
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